Background Financial toxicity is increasingly recognised as adversely affecting the quality of
life and medication adherence in patients with cancer in the USA. Patients with multiple …

What is known and objective Given the increasing healthcare costs and the recent
introduction of novel agents in the treatment for multiple myeloma (MM), an incurable …

Background Treatments for multiple myeloma (MM) have been rapidly evolving. Newly
developed treatment regimens are likely to be more effective but also cost more than …

Background In oncology, health-related quality of life (HRQoL) data are often collected using
disease-specific patient questionnaires while generic, patient-level utility data required for …

Objective: To assess the economic value of carfilzomib (Kyprolis), this study developed the
Kyprolis Global Economic Model (K-GEM), which examined from a United States (US) payer …

Background Aloperine, a natural alkaloid constituent isolated from the herb Sophora
alopecuroides displays anti-inflammatory properties in vitro and in vivo. Our group …

Objectives To study the impact of novel treatments for elderly (≥ 66 yr) patients with multiple
myeloma (MM) in daily practice by comparing real‐world effects [overall survival (OS) and …

Purpose The prominent efficacy of the addition of daratumumab to lenalidomide and
dexamethasone (DRd) or the addition to bortezomib and dexamethasone (DVd) was proven …

Technology drives both health care spending and health improvement. Yet policy makers
rarely see measures of cost growth that account for both effects. To fill this gap, we present …

Background In recent years, the development of new therapies for multiple myeloma has
improved the survival of patients, but newer treatments may also affect healthcare costs. To …